US Cooperative Group Will Test Ivonescimab in Biliary Cancer

Company Akeso; Summit Therapeutics; ECOG-ACRIN Event Type Development Collaboration (registration-enabling Phase 2/3 trial) Modality PD-1/VEGF bispecific antibody Asset Ivonescimab (EA2251) Target PD-1; VEGF Disease Area First-line advanced biliary tract cancer Summary Summit and the US ECOG-ACRIN research group announced a registration-enabling phase 2/3 study of…